Amarin | AMRN - Cost Of Sales

Stock Price
14.75
Daily Change
0.66 4.68%
Monthly
5.13%
Yearly
36.32%
Q1 Forecast
14.47

Amarin reported $16.89M in Cost of Sales for its fiscal quarter ending in March of 2025.





Cost Of Sales Change Date
AbbVie USD 4.55B 757M Dec/2025
Alnylam Pharmaceuticals USD 200.15M 57.2M Sep/2025
Amarin USD 16.89M 18.51M Mar/2025
AstraZeneca USD 2.8B 328M Sep/2025
GlaxoSmithKline GBP 2.61B 377M Dec/2025
Halozyme Therapeutics USD 73M 8.88M Sep/2025
Ionis Pharmaceuticals USD 2.34M 1.81M Sep/2025
Neurocrine Biosciences USD 264M 252.7M Sep/2025
Novartis USD 3.54B 217M Sep/2025